Efficacy And Safety Results Of Ramucirumab In Combination With Osimertinib In Advanced T790m-Positive Egfr-Mutant Nsclc.

9053Background: Progression of EGFR-mutant non-small cell lung cancer (NSCLC) occurs in most patients (pts) despite initial benefit with a first-line EGFR tyrosine kinase inhibitor (TKI). A first- or second generation EGFR TKI + a VEGF- or EGFR-directed monoclonal antibody (mAb) has shown promising results in pts with EGFR-mutant NSCLC. Methods: This ongoing, single-arm, Phase 1study (NCT02789345) enrolled pts with T790M-positive EGFR-mutant (Ex19del or L858R) NSCLC with prior progression on first-line EGFR TKI therapy. The primary phase 1b objective was assessment of safety/tolerability of ramucirumab (Ram), a VEGFR2 mAb, + osimertinib (Osi), a novel third-generation EGFR TKI. Key secondary efficacy endpoints were investigator assessed objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and progression-free survival (PFS). Results: Pts (N = 25) were 45-80 years (median 64) with ECOG-PS 0 (n = 3) or 1 (n = 22) and tobacco history of current (n = 5), former (n = 8), or ne...